Dr Sharon Chan, Head of Asia, Aeras, has over 10 years of pharmaceutical and biotechnology experience. She is based in Beijing, China and oversees, directs and implements Aeras’ vaccine development, resource mobilization, stakeholder relations and other activities in Asia. This includes coordinating research activities for tuberculosis vaccine projects in Asia and serving as the primary link between Aeras, the Bill and Melinda Gates Foundation China Office and government agencies.
Prior to joining Aeras, Dr Chan rose to the position of Associate Director, Business Development at Baxter Healthcare and led all business development activities for China.
She is experienced in identifying, analyzing and negotiating business opportunities across a wide range of therapies in biotechnology, pharmaceutical and medical device sectors. In particular, Dr Chan has led technology transfer, licensing, contract development and manufacturing services and distribution efforts for FSME-Immun, NeisVac-C, PREFLUCEL and CELVAPAN vaccines across Asia Pacific. Prior to Baxter, she held various roles in business development at Sosei, a Japanese biopharmaceutical company, in London, United Kingdom. Dr Chan holds an International Executive MBA from IE Business School, Madrid, Spain and a PhD and Masters in Molecular and Cellular Biochemistry from Oxford University.